Camurus stock
CAMX.STSTOCamurus AB, HealthcareISIN SE0007692850
74Score 74 out of 100, Strong
Price and trend
82 / 100
Price history
+21% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 28% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 75).
The price is at its 52-week high. Largest decline in 11 years: 59% (January 2018 to January 2019).
Chart figures for advanced users
- SMA 50$64.43
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$57.69
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)75
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$43.86
- The lowest closing price of the last twelve months.
- Resistance$74.30
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Camurus AB belongs to the Biotechnology industry (Sweden) and, with a market value of $4.41B, is number 80 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $227.15M (up 21.3% year on year) and earnings of $73.76M (up 71.7%).
- For fiscal 2026, analysts expect on average revenue of $284.34M (up 25.2%) and adjusted earnings per share of $1.51 (up 23.9%).
Show more
- MEQIRI Score 74 out of 100 (Strong): rank 83 of 702 in Healthcare, median 53.
- The P/E is 58.3 (Biotechnology median 21.7, own median of recent years 69.2).
- Our model puts fair value at $165.03, with the price 55% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 130.3% in fiscal 2025, Biotechnology median −24.3%.Profitability 93
- Growing faster than its industryRevenue up 46.5% a year since 2020, Biotechnology median 19.4%.Growth 70
- Analysts expect strong earnings growthUp 45.4% a year through 2028 (estimates from 7 analysts).Growth 70
Weaknesses
- Margin may fall backOperating margin 39%, average of the prior years 7.5%, which ranged from −61.5% to 30.6%. After peaks like this, the margin was more than a quarter lower two years later in 44 of 100 cases, against 24 of 100 for other companies with high margins.
- DilutionShare count up 12% since 2020.Capital allocation 54
- Volatile share priceVolatility 46% a year over the last 12 months.
Its standout strengths are profitability and momentum.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $117.88 and expensive above $275.05 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $302.47 (cash-flow model) and $27.59 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 7.3%. At 8.3% the fair value would be $135.44, at 6.3% it would be $209.42.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 3% on the twelve months before. Revenue has grown strongly since 2012, at around 28% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 93%, operating 39%, net 32%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 18 Feb 2027in 97 days
- Last reported
- 5 Nov 2026EPS reported $0.45 (expected $0.37)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.51+0.8%
- Revenue
- $284.34M+0.3%
- Earnings per share
- $2.16−0.2%
- Revenue
- $375.92M+1.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +21.4%Full-year guidance affirmed despite the FDA complete response letter (CRL) for acromegaly.
“Despite the CRL for acromegaly, we affirm our full-year guidance.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 15 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at Camurus
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 74
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Edgewise TherapeuticsEWTX $4.93B54
- Adaptive BiotechnologiesADPT $4.77B47
- Ionis PharmaceuticalsIONS $4.55B32
- Definium TherapeuticsDFTX $4.52B41
- Tango TherapeuticsTNGX $4.21B46
- CRISPR TherapeuticsCRSP $4.13B34
- Xenon PharmaceuticalsXENE $4.03B35
- Relay TherapeuticsRLAY $3.99B43
ETFs that hold Camurus
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares OMX Stockholm Capped UCITS ETFOM3X | 0.32% | 0.10% | €198.93M |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.21% | 0.23% | €321.86M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.17% | 0.30% | €3.45B |
Show 5 more
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.06% | 0.10% | €395.74M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.03% | 0.45% | €1.54B |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.03% | 0.30% | €813.64M |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.84B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.